Das Fortbildungsportal für Ärztinnen und Ärzte
Online-Fortbildungen für MFA & Praxisteams
Video-Fortbildung

Fettleber und MASH – welche Patienten Sie im Blick haben sollten

1:07 Stunden
online
CME zertifiziert (2 Punkte)
Allgemeinmedizin
Diabetologie
Endokrinologie
Gastroenterologie
Innere Medizin
Adipositas
Diabetes mellitus
MASH
Referent:
Prof. Dr. med. Christoph Sarrazin
Illustration einer Leber aus Puzzleteilen, die von zwei ärztlichen Händen mit Instrumenten zusammengesetzt wird – symbolische Darstellung von Diagnose und Therapie bei Fettleber und MASH.

Weitere Informationen

Die Prävalenz nicht-alkoholischer Fettlebererkrankungen wie der metabolisch dysfunktionsassoziierten steatotischen Lebererkrankung (MASLD) und der Steatohepatitis (MASH) nimmt stetig zu. Aufgrund ihres hohen Risikos für relevante Komorbiditäten – darunter Adipositas, chronische Nierenerkrankungen und kardiovaskuläre Komplikationen – kommt ihnen entlang des gesamten Versorgungspfads besondere Bedeutung zu. In dieser CME-zertifizierten On-Demand-Fortbildung erläutert Prof. Dr. Christoph Sarrazin praxisnah, welche Patient:innen ein erhöhtes Risiko aufweisen und wie eine leitliniengerechte Therapie erfolgreich umgesetzt werden kann.

Was nehme ich fachlich aus dieser Fortbildung mit?
  • Risikofaktoren und relevante Komorbiditäten im Zusammenhang mit metabolischen Lebererkrankungen (MASLD, MASH)
  • Diagnostische Verfahren zur Identifikation der MASLD
  • Aktuelle klinische Studien sowie therapeutische Ansätze bei MASLD und MASH

Hinweise zur Zertifizierung

  • CME-Punkte
    2
    Kategorie
    D
    Zeitraum
    -
    Teilnahmekosten
    kostenlos
    Wissenschaftliche Leitung
    Prof. Dr. Christoph Sarrazin
    Zertifiziert durch
    Landesärztekammer Rheinland-Pfalz
    Veranstalter
    Boehringer Ingelheim Pharma GmbH & Co. KG

Referierende

    • Referenzen

      • Rangaswami, J., Tuttle, K., & Vaduganathan, M. (2020). Cardio-Renal-Metabolic Care Models: Toward Achieving Effective Interdisciplinary Care. Circulation. Cardiovascular quality and outcomes, 13(11), e007264
        Link zum Artikel
      • Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., Despres, J. P., Ho, J. E., Joseph, J. J., Kernan, W. N., Khera, A., Kosiborod, M. N., Lekavich, C. L., Lewis, E. F., Lo, K. B., Ozkan, B., … American Heart Association (2023). Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation, 148(20), 1606–1635.
        Link zum Artikel
      • Ndumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., Coresh, J., Baker-Smith, C. M., Carnethon, M. R., Després, J. P., Ho, J. E., Joseph, J. J., Kernan, W. N., Khera, A., Kosiborod, M. N., Lekavich, C. L., Lewis, E. F., Lo, K. B., Ozkan, B., Palaniappan, L. P., … American Heart Association (2023). A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation, 148(20), 1636–1664.
        Link zum Artikel
      • Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023). AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology (Baltimore, Md.), 77(5), 1797–1835.
        Link zum Artikel
      • Definition & Facts of NAFLD & NASH. (2021, April). National Institute Of Diabetes And Digestive And Kidney Diseases. Abgerufen am Juni 2025, von https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/definition-facts
      • European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of hepatology, 81(3), 492–542.
        Link zum Artikel
      • Multinational liver societies announce new “Fatty” liver disease nomenclature that is affirmative and non-stigmatising. (2023, 5. Juli). EASL-The Home Of Hepatology. Abgerufen am Juni 2025, von https://easl.eu/news/new_fatty_liver_disease_nomenclature-2/
      • Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023). The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology (Baltimore, Md.), 77(4), 1335–1347.
        Link zum Artikel
      • Huang, D. Q., Mathurin, P., Cortez-Pinto, H., & Loomba, R. (2023). Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nature reviews. Gastroenterology & hepatology, 20(1), 37–49.
        Link zum Artikel
      • Roeb, E., Canbay, A., Bantel, H., Bojunga, J., de Laffolie, J., Demir, M., Denzer, U. W., Geier, A., Hofmann, W. P., Hudert, C., Karlas, T., Krawczyk, M., Longerich, T., Lüdde, T., Roden, M., Schattenberg, J. M., Sterneck, M., Tannapfel, A., Lorenz, P., Tacke, F., … Collaborators (2024). Amendment „Neue Nomenklatur zur MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease; metabolische Dysfunktion assoziierte steatotische Lebererkrankung)“ zur S2k-Leitlinie „Nicht-alkoholische Fettlebererkrankung“ (v.2.0/April 2022) der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Zeitschrift für Gastroenterologie, 62(7), 1077–1087.
        Link zum Artikel
      • Younossi, Z. M., Golabi, P., Price, J. K., Owrangi, S., Gundu-Rao, N., Satchi, R., & Paik, J. M. (2024). The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 22(10), 1999–2010.e8.
        Link zum Artikel
      • Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A. A. (2022). The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. The lancet. Gastroenterology & hepatology, 7(9), 851–861.
        Link zum Artikel
      • Le, M. H., Yeo, Y. H., Zou, B., Barnet, S., Henry, L., Cheung, R., & Nguyen, M. H. (2022). Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clinical and molecular hepatology, 28(4), 841–850.
        Link zum Artikel
      • Pirillo, A., Casula, M., Olmastroni, E., Norata, G. D., & Catapano, A. L. (2021). Global epidemiology of dyslipidaemias. Nature reviews. Cardiology, 18(10), 689–700.
        Link zum Artikel
      • Fernando, D. H., Forbes, J. M., Angus, P. W., & Herath, C. B. (2019). Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products. International journal of molecular sciences, 20(20), 5037.
        Link zum Artikel
      • NCD Risk Factor Collaboration (NCD-RisC) (2021). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet (London, England), 398(10304), 957–980.
        Link zum Artikel
      • Lobstein, T., Powis, J., Jackson-Leach, R. & World Obesity Federation. (2024). World Obesity Atlas 2024. In World Obesity Federation, World Obesity Federation. World Obesity Federation. Abgerufen am August 2024, von https://data.worldobesity.org/publications/?cat=22
      • Jager, K. J., Kovesdy, C., Langham, R., Rosenberg, M., Jha, V., & Zoccali, C. (2019). A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney international, 96(5), 1048–1050.
        Link zum Artikel
      • GBD 2019 Diseases and Injuries Collaborators. (2020). Global burden of disease study 2019 (GBD 2019) results: Cardiovascular diseases. The Lancet.
        Link zum Artikel
      • GBD 2021 Diabetes Collaborators (2023). Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet (London, England), 402(10397), 203–234
        Link zum Artikel
      • GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England), 392(10159), 1789–1858.
        Link zum Artikel
      • Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.), 67(1), 328–357.
        Link zum Artikel
      • Povsic, M., Wong, O. Y., Perry, R., & Bottomley, J. (2019). A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH). Advances in therapy, 36(7), 1574–1594.
        Link zum Artikel
      • Younossi, Z. M., Blissett, D., Blissett, R., Henry, L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R. (2016). The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology (Baltimore, Md.), 64(5), 1577–1586.
        Link zum Artikel
      • Cheung, A., & Ahmed, A. (2021). Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks. Clinical and experimental gastroenterology, 14, 457–465.
        Link zum Artikel
      • Miller, A., McNamara, J., Hummel, S. L., Konerman, M. C., & Tincopa, M. A. (2020). Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction. Scientific reports, 10(1), 12440.
        Link zum Artikel
      • Toh, J. Z. K., Pan, X. H., Tay, P. W. L., Ng, C. H., Yong, J. N., Xiao, J., Koh, J. H., Tan, E. Y., Tan, E. X. X., Dan, Y. Y., Loh, P. H., Foo, R., Chew, N. W. S., Sanyal, A. J., Muthiah, M. D., & Siddiqui, M. S. (2022). A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 20(11), 2462–2473.e10.
        Link zum Artikel
      • Whitsett, M., Wilcox, J., Yang, A., Zhao, L., Rinella, M., & VanWagner, L. B. (2019). Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis. Liver international : official journal of the International Association for the Study of the Liver, 39(5), 933–940.
        Link zum Artikel
      • Falzarano, C., Lofton, T., Osei-Ntansah, A., Oliver, T., Southward, T., Stewart, S., & Andrisse, S. (2022). Nonalcoholic Fatty Liver Disease in Women and Girls With Polycystic Ovary Syndrome. The Journal of clinical endocrinology and metabolism, 107(1), 258–272.
        Link zum Artikel
      • Ma, W., Wu, W., Wen, W., Xu, F., Han, D., Lyu, J., & Huang, Y. (2022). Association of NAFLD with cardiovascular disease and all-cause mortality: a large-scale prospective cohort study based on UK Biobank. Therapeutic advances in chronic disease, 13, 20406223221122478.
        Link zum Artikel
      • Sanyal, A. J., Husain, M., Diab, C., Mangla, K. K., Shoeb, A., Lingvay, I., & Tapper, E. B. (2024). Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review. American heart journal plus : cardiology research and practice, 41, 100386.
        Link zum Artikel
      • Driessen, S., Francque, S. M., Anker, S. D., Castro Cabezas, M., Grobbee, D. E., Tushuizen, M. E., & Holleboom, A. G. (2025). Metabolic dysfunction-associated steatotic liver disease and the heart. Hepatology (Baltimore, Md.), 82(2), 487–503.
        Link zum Artikel
      • Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J. P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., St-Onge, M. P., & American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation, 143(21), e984–e1010.
        Link zum Artikel
      • Pisto, P., Santaniemi, M., Bloigu, R., Ukkola, O., & Kesäniemi, Y. A. (2014). Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study. BMJ open, 4(3), e004973.
        Link zum Artikel
      • Quek, J., Chan, K. E., Wong, Z. Y., Tan, C., Tan, B., Lim, W. H., Tan, D. J. H., Tang, A. S. P., Tay, P., Xiao, J., Yong, J. N., Zeng, R. W., Chew, N. W. S., Nah, B., Kulkarni, A., Siddiqui, M. S., Dan, Y. Y., Wong, V. W., Sanyal, A. J., Noureddin, M., … Ng, C. H. (2023). Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. The lancet. Gastroenterology & hepatology, 8(1), 20–30.
        Link zum Artikel
      • Vinciguerra, F., Baratta, R., Farina, M. G., Tita, P., Padova, G., Vigneri, R., & Frittitta, L. (2013). Very severely obese patients have a high prevalence of type 2 diabetes mellitus and cardiovascular disease. Acta diabetologica, 50(3), 443–449.
        Link zum Artikel
      • Pantalone, K. M., Hobbs, T. M., Chagin, K. M., Kong, S. X., Wells, B. J., Kattan, M. W., Bouchard, J., Sakurada, B., Milinovich, A., Weng, W., Bauman, J., Misra-Hebert, A. D., Zimmerman, R. S., & Burguera, B. (2017). Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system. BMJ open, 7(11), e017583.
        Link zum Artikel
      • Schienkiewitz, A., Mensink, G. B., & Scheidt-Nave, C. (2012). Comorbidity of overweight and obesity in a nationally representative sample of German adults aged 18-79 years. BMC public health, 12, 658.
        Link zum Artikel
      • Arinsoy, T., Deger, S. M., Ates, K., Altun, B., Ecder, T., Camsari, T., Serdengecti, K., & Suleymanlar, G. (2016). Prevalence of Chronic Kidney Disease in Turkish Adults With Obesity and Metabolic Syndrome: A Post Hoc Analysis from Chronic Renal Disease in Turkey Study. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 26(6), 373–379.
        Link zum Artikel
      • Yim, H. E., & Yoo, K. H. (2021). Obesity and chronic kidney disease: prevalence, mechanism, and management. Clinical and experimental pediatrics, 64(10), 511–518.
        Link zum Artikel
      • Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016). The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism: clinical and experimental, 65(8), 1038–1048.
        Link zum Artikel
      • Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005). Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. The Journal of clinical investigation, 115(5), 1343–1351.
        Link zum Artikel
      • Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018). Mechanisms of NAFLD development and therapeutic strategies. Nature medicine, 24(7), 908–922.
        Link zum Artikel
      • Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018). Triggering and resolution of inflammation in NASH. Nature reviews. Gastroenterology & hepatology, 15(6), 349–364.
        Link zum Artikel
      • Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., Wilson, L. A., Yates, K. P., Belt, P., Lazo, M., Kleiner, D. E., Behling, C., Tonascia, J., & NASH Clinical Research Network (CRN) (2021). Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. The New England journal of medicine, 385(17), 1559–1569.
        Link zum Artikel
      • Tsuchida, T., & Friedman, S. L. (2017). Mechanisms of hepatic stellate cell activation. Nature reviews. Gastroenterology & hepatology, 14(7), 397–411.
        Link zum Artikel
      • Wegermann, K., Diehl, A. M., & Moylan, C. A. (2018). Disease pathways and molecular mechanisms of nonalcoholic steatohepatitis. Clinical liver disease, 11(4), 87–91.
        Link zum Artikel
      • Chiang, D. J., Pritchard, M. T., & Nagy, L. E. (2011). Obesity, diabetes mellitus, and liver fibrosis. American journal of physiology. Gastrointestinal and liver physiology, 300(5), G697–G702.
        Link zum Artikel
      • Ratziu, V., Goodman, Z., & Sanyal, A. (2015). Current efforts and trends in the treatment of NASH. Journal of hepatology, 62(1 Suppl), S65–S75.
        Link zum Artikel
      • Torok N. J. (2015). Vascular adhesion protein 1 in nonalcoholic steatohepatitis: a novel biomarker?. Hepatology (Baltimore, Md.), 62(4), 1313–1315.
        Link zum Artikel
      • Honda, Y., Yoneda, M., Imajo, K., & Nakajima, A. (2020). Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. International journal of molecular sciences, 21(11), 4039.
        Link zum Artikel
      • Kleiner, D. E., Brunt, E. M., Wilson, L. A., Behling, C., Guy, C., Contos, M., Cummings, O., Yeh, M., Gill, R., Chalasani, N., Neuschwander-Tetri, B. A., Diehl, A. M., Dasarathy, S., Terrault, N., Kowdley, K., Loomba, R., Belt, P., Tonascia, J., Lavine, J. E., Sanyal, A. J., … Nonalcoholic Steatohepatitis Clinical Research Network (2019). Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA network open, 2(10), e1912565.
        Link zum Artikel
      • D'Amico, G., Garcia-Tsao, G., & Pagliaro, L. (2006). Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. Journal of hepatology, 44(1), 217–231.
        Link zum Artikel
      • Garcia-Tsao, G., Abraldes, J. G., Berzigotti, A., & Bosch, J. (2017). Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology (Baltimore, Md.), 65(1), 310–335.
        Link zum Artikel
      • European Association For The Study Of The Liver (2023). Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series' [J Hepatol 73 (2020) 1170-1218]. Journal of hepatology, 78(2), 452.
        Link zum Artikel
      • Eskridge, W., Cryer, D. R., Schattenberg, J. M., Gastaldelli, A., Malhi, H., Allen, A. M., Noureddin, M., & Sanyal, A. J. (2023). Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective. Journal of clinical medicine, 12(19), 6216.
        Link zum Artikel
      • Cholongitas, E., Pavlopoulou, I., Papatheodoridi, M., Markakis, G. E., Bouras, E., Haidich, A. B., & Papatheodoridis, G. (2021). Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis. Annals of gastroenterology, 34(3), 404–414.
        Link zum Artikel
      • European Association for the Study of the Liver (2021). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. Journal of hepatology, 75(3), 659–689.
        Link zum Artikel
      • Pandey, N., Hoilat, G. J., & John, S. (2023). Liver Biopsy. In StatPearls. StatPearls Publishing.
        Link zum Artikel
      • Zoncapè, M., Liguori, A., & Tsochatzis, E. A. (2024). Non-invasive testing and risk-stratification in patients with MASLD. European journal of internal medicine, 122, 11–19.
        Link zum Artikel
      • Canivet, C. M., & Boursier, J. (2022). Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022?. Diagnostics (Basel, Switzerland), 13(1), 91.
        Link zum Artikel
      • Younossi, Z. M., Zelber-Sagi, S., Lazarus, J. V., Wong, V. W., Yilmaz, Y., Duseja, A., Eguchi, Y., Castera, L., Pessoa, M. G., Oliveira, C. P., El-Kassas, M., Tsochatzis, E., Fan, J. G., Spearman, C. W., Tacke, F., Castellanos Fernandez, M. I., Alkhouri, N., Schattenberg, J. M., Romero-Gómez, M., Noureddin, M., … Alqahtani, S. A. (2025). Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Gastroenterology, 169(5), 1017–1032.e2.
        Link zum Artikel
      • Roeb, E., Canbay, A., Bantel, H., Bojunga, J., de Laffolie, J., Demir, M., Denzer, U. W., Geier, A., Hofmann, W. P., Hudert, C., Karlas, T., Krawczyk, M., Longerich, T., Luedde, T., Roden, M., Schattenberg, J., Sterneck, M., Tannapfel, A., Lorenz, P., Tacke, F., … Collaborators: (2022). Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025. Zeitschrift für Gastroenterologie, 60(9), 1346–1421
        Link zum Artikel
      • Allen, A. M., Charlton, M., Cusi, K., Harrison, S. A., Kowdley, K. V., Noureddin, M., & Shubrook, J. H. (2024). Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting. Postgraduate medicine, 136(3), 229–245.
        Link zum Artikel
      • Madrigal Pharmaceuticals. (2024). HIGHLIGHTS OF PRESCRIBING INFORMATION [Prescribing information].
        Link zum Artikel
      • Boettcher, E., Csako, G., Pucino, F., Wesley, R., & Loomba, R. (2012). Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Alimentary pharmacology & therapeutics, 35(1), 66–75.
        Link zum Artikel
      • Johnston, M. P., Patel, J., & Byrne, C. D. (2020). Multi-drug approaches to NASH: what's in the development pipeline?. Expert opinion on investigational drugs, 29(2), 143–150
        Link zum Artikel
      • Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015). Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology, 149(2), 367–e15.
        Link zum Artikel
      • Lassailly, G., Caiazzo, R., Ntandja-Wandji, L. C., Gnemmi, V., Baud, G., Verkindt, H., Ningarhari, M., Louvet, A., Leteurtre, E., Raverdy, V., Dharancy, S., Pattou, F., & Mathurin, P. (2020). Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology, 159(4), 1290–1301.e5.
        Link zum Artikel
      • Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., Hosseini-Tabatabaei, A., Schattenberg, J. M., Noureddin, M., Alkhouri, N., Younes, R., & 1404-0043 Trial Investigators (2024). A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. The New England journal of medicine, 391(4), 311–319.
        Link zum Artikel
      • Harrison, S. A., Browne, S. K., Suschak, J. J., Tomah, S., Gutierrez, J. A., Yang, J., Roberts, M. S., & Harris, M. S. (2025). Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. Journal of hepatology, 82(1), 7–17.
        Link zum Artikel
      • Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., Haupt, A., & Hartman, M. L. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine, 30(7), 2037–2048.
        Link zum Artikel
      • Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A. S., Harrison, S. A., & NN9931-4296 Investigators (2021). A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. The New England journal of medicine, 384(12), 1113–1124.
        Link zum Artikel
      • Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., Brouwers, B., Robins, D. A., Nikooie, A., Bunck, M. C., Haupt, A., Sanyal, A. J., & SYNERGY-NASH Investigators (2024). Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. The New England journal of medicine, 391(4), 299–310.
        Link zum Artikel
      • Harrison, S. A., Frias, J. P., Lucas, K. J., Reiss, G., Neff, G., Bollepalli, S., Su, Y., Chan, D., Tillman, E. J., Moulton, A., de Temple, B., Zari, A., Shringarpure, R., Rolph, T., Cheng, A., & Yale, K. (2025). Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 23(1), 103–113.
        Link zum Artikel
      • Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., Gottwald, M. D., Feng, S., Agollah, G. D., Hartsfield, C. L., Mansbach, H., Margalit, M., & Abdelmalek, M. F. (2023). Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. The New England journal of medicine, 389(11), 998–1008.
        Link zum Artikel
      • Noureddin, M., Kowdley, K. V., Odrljin, T., Bain, G., Zhao, J., Jeglinski, B., Koziel, M. J., & Loomba, R. (2026). Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England), 407(10530), 794–804.
        Link zum Artikel
      • Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., Anstee, Q. M., Abdelmalek, M. F., Younossi, Z., Baum, S. J., Francque, S., Charlton, M. R., Newsome, P. N., Lanthier, N., Schiefke, I., Mangia, A., … MAESTRO-NASH Investigators (2024). A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. The New England journal of medicine, 390(6), 497–509.
        Link zum Artikel
      • Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., Lanthier, N., Alkhouri, N., Moreno, C., Schattenberg, J. M., Stefanova-Petrova, D., Vonghia, L., Rouzier, R., Guillaume, M., Hodge, A., Romero-Gómez, M., … NATIVE Study Group (2021). A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. The New England journal of medicine, 385(17), 1547–1558.
        Link zum Artikel
      • Harrison, S. A., Taub, R., Neff, G. W., Lucas, K. J., Labriola, D., Moussa, S. E., Alkhouri, N., & Bashir, M. R. (2023). Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nature medicine, 29(11), 2919–2928.
        Link zum Artikel
      • Alkhouri, N., Taub, R., Lu, X., Pushkin, R., Charlton, M. R., Moussa, S., Kohli, A., Noureddin, M., & Schattenberg, J. M. (2025, May 7–10). Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in patients with compensated MASH cirrhosis (Abstract LBO-002) [Oral presentation]. EASL Congress 2025, Amsterdam, Netherlands. Journal of Hepatology, 82(1).
        Link zum Artikel
      • Roeb, E., et al. (2025). Amendment „Resmetirom“ zur S2k-Leitlinie „Metabolische Lebererkrankungen“ (vormals „Nicht-alkoholische Fettlebererkrankung v.2.0 / April 2022) der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 2.3). In Amendment der S2k-Leitlinie MASLD [Report].
        Link zum Artikel
      • Leber, Galle, Pankreas Archive - DGVS - Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten. (o. D.). DGVS - Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten.
        Link zum Artikel
      • Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M., Bugianesi, E., Rinella, M. E., Roden, M. & Ratziu, V. (2025). Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. New England Journal Of Medicine, 392(21), 2089–2099.
        Link zum Artikel
      • Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., Anstee, Q. M., Abdelmalek, M. F., Younossi, Z., Baum, S. J., Francque, S., Charlton, M. R., Newsome, P. N., Lanthier, N., Schiefke, I., . . . Ratziu, V. (2024). A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. New England Journal Of Medicine, 390(6), 497–509.
        Link zum Artikel
      • Newsome, P. N., Armstrong, M. J., Bakulin, I., et al. (2025, November 7–11). Weight-dependent and -independent effects of semaglutide in participants with MASH: Secondary analysis of the phase 3 ESSENCE trial (Abstract 0010) [Conference presentation]. The Liver Meeting, Washington, DC, United States.
        Link zum Artikel
      • Loomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., Newsome, P. N., & NN9931-4492 investigators (2023). Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. The lancet. Gastroenterology & hepatology, 8(6), 511–522.
        Link zum Artikel
      • Sanyal, A., Bedossa, P., Fraessdorf, M., et al. (2024, June 7). GS-006 glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial [Oral presentation]. EASL Congress 2024, Milan, Italy. Journal of Hepatology, 80(Suppl. 1), S4–S5.
        Link zum Artikel

       

SC-DE-08535

  1. mediakademie.de
  2. CME‑Fortbildungen
  3. Allgemeinmedizin/Innere Medizin
  4. Fettleber und MASH - welche Patienten im Blick